Results 111 to 120 of about 16,895 (259)
The PARAGON Heart Failure trial – ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction [PDF]
Sverre E. Kjeldsen +3 more
openalex +1 more source
Urinary neprilysin – Another marker to predict postoperative acute kidney injury
Abhijit Nair, Suresh Seelam
openalex +1 more source
Abstract Over the past three decades, there has been a steady increase in clinical attention to ischaemic heart failure caused by coronary microembolization. Nonetheless, a suitable mouse model for studying this condition remains limited. In the present study, we developed a mouse model of coronary microembolization‐induced ischaemic heart failure by ...
Lang Pei +10 more
wiley +1 more source
Copper Transporters? Glutathione Reactivity of Products of Cu–Aβ Digestion by Neprilysin [PDF]
Ewelina Stefaniak +4 more
openalex +1 more source
Ablation of Ventricular Tachycardia Using the QDOT MICRO Ablation Catheter (VT‐MICRO Study)
Catheter ablation is useful to treat patients with ventricular tachycardia. QDOT Micro catheter is a next generation catheter designed to provide more efficient lesion creation with an accurate myocardial substrate analysis. Microelectrode mapping allows detection of higher voltage electrograms compared to standard bipolar mapping and Pentaray mapping.
Antonio Di Monaco +6 more
wiley +1 more source
Angiotensin receptor/neprilysin inhibitor: a novel therapy in the treatment of heart failure
Rohini Gupta +2 more
openalex +2 more sources
Abstract Aims Survodutide is an investigational glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist that has shown promise for treating obesity and its complications in Phase 2 trials. Two double‐blind, randomized, global Phase 3 trials are designed to assess the efficacy and safety of survodutide for treatment of obesity—SYNCHRONIZE™‐1 in ...
Sean Wharton +9 more
wiley +1 more source
Spotlight on valsartan–sacubitril fixed-dose combination for heart failure: the evidence to date
José Fernando Vilela-Martin Internal Medicine Department, São José do Rio Preto State Medical School (FAMERP), São José do Rio Preto, Brazil Abstract: Heart failure is a global problem with elevated prevalence, and it
Vilela-Martin JF
doaj

